The short version of peptide research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-20 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
On July 4, ceremonies took place at Lincoln Financial Field in Philadelphia (Paraguay vs France) and NRG Stadium in Houston (Canada vs Morocco) to honor the United States Semiquincentennial. The Houston ceremony featured pyrotechnics, video-board graphics, and a performance of "The Star-Spangled Banner" by United States Navy Band Chief Musician Maia Rodriguez. The Philadelphia ceremony featured pyrotechnics, video-board signage, and a performance of "The Star-Spangled Banner" by Idina Menzel, as well as musical performances by the Roots, ceremonial elements featuring the Philadelphia Boys Choir & Chorale and Miss Pennsylvania, Stephanie Skinner, a card stunt, a flyby of VFA-11 and VFA-81 squadrons from Naval Air Station Oceana, and a halftime show from DJ Jazzy Jeff.
== Further reading == Calmes, M.; Daunis, J. (1999). "How to build optically active α-amino acids". Amino Acids. 16 (3–4): 215–250. doi:10.1007/BF01388170. PMID 10399014. S2CID 36591079. Han, Y.; Lin, J.; Liao, S.; Qiu, W.; Cai, C.; Hruby, V.J. (2002). "Stereoselective synthesis of highly topographically constrained β-isopropyl substituted aromatic amino acids". In Tam, J.P.; Kaumaya, P.T.P. (eds.). Peptides Frontiers of Peptide Science. American Peptide Symposia. Vol. 5. Springer. pp. 241–243. doi:10.1007/0-306-46862-X_98. ISBN 0-7923-5160-6.
Water extraction: Coffee beans are soaked in water. The water, which contains many other compounds in addition to caffeine and contributes to the flavor of coffee, is then passed through activated charcoal, which removes the caffeine. The water can then be put back with the beans and evaporated dry, leaving decaffeinated coffee with its original flavor. Supercritical carbon dioxide extraction: Supercritical carbon dioxide is an excellent nonpolar solvent for caffeine, and is safer than the organic solvents that are otherwise used. The extraction process is simple: CO2 is forced through the green coffee beans at temperatures above 31.1 °C and pressures above 73 atm. Under these conditions, CO2 is in a "supercritical" state: It has gaslike properties that allow it to penetrate deep into the beans but also liquid-like properties that dissolve 97–99% of the caffeine. The caffeine-laden CO2 is then sprayed with high-pressure water to remove the caffeine. The caffeine can then be isolated by charcoal adsorption (as above) or by distillation, recrystallization, or reverse osmosis. Extraction by organic solvents: Certain organic solvents such as ethyl acetate present much less health and environmental hazard than chlorinated and aromatic organic solvents used formerly. Another method is to use triglyceride oils obtained from spent coffee grounds. Decaffeination does not happen completely; some caffeine remains in the coffee beans. Some commercially available decaffeinated coffee products contain considerable levels.
Sources: en.wikipedia.org
Nights were spent camping on riverbanks, where hammocks were usually slung between trees or, when trees were absent, from canoe paddles or on ox-hides. This exposed the expedition to risks from snakes, alligators, and jaguars, which were especially prevalent and feared by local Natives. Nighttime was often unsettled due to animal activity, including monkeys, peccaries, sloths, and birds.Shortly after departure, a sudden squall nearly overturned the canoe, but a shift in wind stabilized the vessel. The following morning, the expedition encountered a Carib family traveling from the mouth of the Orinoco to collect turtle eggs, an event that attracted hundreds of Natives from various tribes and a few white traders. The eggs were rendered for oil, used for cooking and lighting, though overharvesting threatened the turtle population. At the Island of the Tortoises, Native tribes gathered annually to harvest turtle eggs, each tribe distinguished by unique body paint. Humboldt observed the process and noted that the previous Jesuit supervisors had ensured some eggs were left to hatch, but that their successors, the Franciscans, did not exercise such care, causing a decline in the turtle population. The Native crew from San Fernando departed at the turtle islands, as they lacked experience with the rapids ahead. The expedition switched to a smaller, less comfortable canoe, fashioned from a single tree trunk, which further limited space and increased exposure to environmental discomforts.
Limited maceration, early pressing, and early racking to limit contact time of the LAB with potential nutrient sources Maintain sulfur dioxide levels to at least 25 ppm of "free" (unbound) SO2, depending on the pH of the wine, this may mean an addition of 50–100 mg/L of SO2 Maintain pH levels below 3.3 Keep the wine cool at temperatures between 10 and 14 °C (50. 0 to 57.2 °F) Filter the wine at bottling with at least a 0.45-micron membrane filter to prevent any bacteria from making it into the bottle In addition, winemakers can use chemical and biological inhibitors such as lysozyme, nisin, dimethyl dicarbonate (Velcorin), and fumaric acid, though some (like Verlcorin) are restricted in winemaking countries outside the United States. Fining agents, such as bentonite, and putting the wine through cold stabilization will also remove potential nutrients for LAB, thus inhibiting malolactic fermentation. Some experimentation with the use of bacteriophages (viruses that infect bacteria) has been conducted to limit malolactic fermentations, but disappointing results in the cheesemaking industry have led to skepticism about the practical use of bacteriophages in winemaking.
=== Other === In 2009, LifeVantage was sued by Utah-based Zrii LLC, a marketer of nutritional fruit drinks endorsed by Deepak Chopra, based on allegations that LifeVantage had conspired with former Zrii executives to "ruin the company" and take it over “on the cheap” following a "mass exodus". The case was closed in December 2009 following LifeVantage's settlement payment of $400,000 to Zrii. On October 14, 2011, Burke Hedges, a former LifeVantage distributor (hired for his background as a speaker and trainer) filed a lawsuit with the Utah District Court against LifeVantage and its executives, seeking $3 million in punitive damages over allegations of wrongful termination and tortious interference. In September 2016, a class action lawsuit was filed against LifeVantage in Utah alleging that the company and its executive Darren Jensen and Mark Jaggi made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the case alleged that the defendants made false and/or misleading statements and/or failed to disclose that: (i) LifeVantage lacked effective internal financial controls; (ii) as a result, the Company had improperly accounted for sales in certain international markets, along with associated revenue and income tax accruals; and (iii) as a result of the foregoing, LifeVantage's public statements were materially false and misleading at all relevant times. The case was dismissed in June 2017.
== Further reading == Al-Hussainy, Abbas Ali Abbas, "The civilized achievements of the Akkadian king Naram-Sin A Research in his Artistic Remains and The Date Formulas", ISIN Journal 3, 2022 Boissier, Alfred, "Inscription de Naram-Sin", Revue d’Assyriologie et d’archéologie Orientale, vol. 16, no. 3, pp. 157–64, 1919 Foster, B. R., "Naram-Sin in Martu and Magan", ARRIM 8, pp. 25–44, 1990 Glassner, J. J., "Naram-Sîn Poliorcète. Les avatars d'une sentence divinatoire", Revue d’Assyriologie et d’archéologie Orientale, vol. 77, no. 1, pp. 3–10, 1983 Grayson, A. Kirk, and Edmond Sollberger, "L’insurrection générale contre Narām-Suen", RA70, pp. 103–128, 1976 Lafont, Bertrand, "Une plaque en argile portant une inscription de Naram-Sin d'Agadé", The Third Millennium. Studies in Early Mesopotamia and Syria in Honor of Walter Sommerfeld and Manfred Krebernik, hrsg. v. Arkhipov, Ilya, Kogan, Leonid, Koslova, Natalia (Cuneiform Monographs 50), pp. 408–416, 2020 Piotr Michalowski, "New Sources concerning the Reign of Naram-Sin", Journal of Cuneiform Studies, vol. 32, no. 4, pp. 233–246, (Oct., 1980) Nassouhi, Essad, "Un vase en albatre de Naram - Sin", Revue d’Assyriologie et d’archéologie Orientale, vol. 22, no. 2, pp. 91–91, 1925 [12] A. Poebel, "The ‘Schachtelsatz’ Construction of the Naram-Sîn Text RA XVI 157f.", Miscellaneous Studies, AS 14; Chicago, pp.23–42, 1947 Powell, Marvin A., "Narām-Sîn, Son of Sargon: Ancient History, Famous Names, and a Famous Babylonian Forgery", Zeitschrift für Assyriologie und Vorderasiatische Archäologie, vol. 81, no. 1-2, pp.
Sources: en.wikipedia.org
In April 2023, President Lula began his four-day trip during which he called Portugal relations with Brazil "extraordinary" and stated that "Portugal is not simply a foreign country but our home extension". In the 13th Brazil-Portugal Summit the countries signed several agreements such as a mutual recognition of professional degrees, driver's licenses, rights of persons with disabilities and a witness protection programme in both countries. Other agreements signed during the visit include education, science, tourism, energy and audiovisual areas. Lula also attended a high-level Brazilian-Portuguese business meeting in Matosinhos in which Brazilian aerospace giant Embraer and four Portuguese companies (OGMA, EMPORDEF, GMVIS Skysof and CEiiA) announced a deal to build a Brazilian-designed aircraft. Also in the meeting, Prime Minister António Costa announced Portugal companies EDP and Galp will be investing a total of €5.7 billion in projects in Brazil over the next years. On 24 April, Lula took part in a ceremony at the Queluz Palace to award Brazilian singer and songwriter Chico Buarque the Camões Prize.
=== Pharmacokinetics === Buserelin is ineffective via oral administration due to first-pass metabolism in the gastrointestinal tract. Its bioavailability is 2.5 to 3.3% by intranasal administration and 70% by subcutaneous injection. The plasma protein binding of buserelin is approximately 15%. The metabolism of buserelin occurs in the liver, kidneys, and gastrointestinal tract and is mediated by peptidases, specifically pyroglutamyl peptidase and chymotrypsin-like endopeptidase. The elimination half-life of buserelin regardless of route of administration is about 72 to 80 minutes. Buserelin and its metabolites are eliminated in urine and bile, with approximately 50% of buserelin excreted in urine unchanged.
Camurus aims to collaborate with biotechnology and pharmaceutical companies worldwide to enable and improve the delivery of a wide range of drug compounds. These compounds including peptides, proteins, and insoluble small molecules make use of delivery solutions ranging from long-acting depots to lipid nanocarriers designed for improved intravenous, transdermal, and oral delivery. Camurus' in-house product portfolio targets healthcare needs in areas of growth-hormone disorders, cancer, oncology supportive care, metabolic disease, and drug addiction. In 2007, British investors evaluated six nominated private companies and chose to Camurus as the best privately owned biotechnology company in the Medicon Valley. The company was awarded the Strictly Financing Award 2007. In 2013, Camurus was awarded CPhI Pharma Award for Best Innovation in Formulation.
IOM Research Report TM/05/03 A normative study of levels of uranium in the urine of personnel in the British Forces Archived 26 July 2011 at the Wayback Machine by B. G. Miller, A. P. Colvin, P. A. Hutchison, H. Tait, S. Dempsey, D. Lewis, C. A. Soutar. IOM Research Report TM/05/08 Opinion on the environmental and health risks posed by depleted uranium by the Scientific Committee on Health and Environmental Risks
=== Mechanism of action === Insulin glargine differs from human insulin by replacing asparagine with glycine in position 21 of the A-chain and by carboxy-terminal extension of B-chain by 2 arginine residues. The arginine amino acids shift the isoelectric point from a pH of 5.4 to 6.7, making the molecule more soluble at an acidic pH and less soluble at physiological pH. The isoelectric shift also allows for the subcutaneous injection of a clear solution. The glycine substitution prevents deamidation of the acid-sensitive asparagine at acidic pH. In the neutral subcutaneous space, higher-order aggregates form, resulting in a slow, peakless dissolution and absorption of insulin from the site of injection.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.